November 10, 2025

FDA Proposes Removal of Box Warnings

The FDA proposed updates to menopausal hormone therapy labeling to reflect current evidence on benefits and risks.

Conexiant

November 04, 2025

FDA Approves First Drug for Thymidine Kinase 2 Deficiency

First-ever treatment shows significant survival benefit in matched-pair analysis of this ultra-rare mitochondrial depletion syndrome.

Conexiant

October 31, 2025

EU Approval for OFA® Analyzer

The CE Mark certification of Konan Medical’s OFA marks a revolution in objective visual testing in Europe, enhancing patient care.

The Ophthalmologist

October 30, 2025

Summarizing the Big Events in the Small Molecules Field

October 2025 highlights in the small molecules sector include developments in dermatitis treatment, improvements in epilepsy symptoms, and the effects of amoxicillin availability.

The Medicine Maker

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 16, 2025

HHS Memo: Fringe Finds a Footing

From wheat fields to Washington: a decades-old fear about skies and 'sprays' rises again, colliding with science, social media, and the machinery of federal policymaking.

KFF Health News

October 16, 2025

Depression Risk Rises Among Gabapentin Users

Gabapentin is most strongly associated with depression among women, lower-income patients, and those who sleep fewer than 7 hours per night.

Conexiant